HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.
Read original at benzingaStocks · News reference
8-K filing — REGENXBIO Inc. (RGNX)
Filed: 2026-08-25 AccNo: 0001193125-26-365287 Size: 203 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 25, 2026, 8:57 PM
- Checked
- Aug 25, 2026, 8:57 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.
Read original at benzingaCrude Oil Down 3%; XPeng Shares Fall After Q2 Results
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected loss and lower revenue outlook.
Read original at benzinga